loading...| Preferred Name | Nateglinide | |
| Synonyms |
|
|
| Definitions |
A phenylalanine derivative of the meglitinide class of agents with hypoglycemic activity. Nateglinide, compared to repaglitinide, binds with a higher affinity to the SUR1 subunit and with a faster onset of action and a shorter duration of action. This agent is metabolized by the cytochrome P450 isoenzyme CYP2C9, and, to a lesser extent, by CYP3A4. The parent drug and metabolites are mainly excreted in the urine and its half-life is about 1.5 hours. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C61858 |
|
| CAS_Registry |
105816-04-4 |
|
| Chemical_Formula |
C19H27NO3 |
|
| code |
C61858 |
|
| Contributing_Source |
FDA |
|
| definition |
A phenylalanine derivative of the meglitinide class of agents with hypoglycemic activity. Nateglinide, compared to repaglitinide, binds with a higher affinity to the SUR1 subunit and with a faster onset of action and a shorter duration of action. This agent is metabolized by the cytochrome P450 isoenzyme CYP2C9, and, to a lesser extent, by CYP3A4. The parent drug and metabolites are mainly excreted in the urine and its half-life is about 1.5 hours. |
|
| FDA_UNII_Code |
41X3PWK4O2 |
|
| in_subset | ||
| label |
Nateglinide |
|
| Legacy Concept Name |
Nateglinide |
|
| NCI_Drug_Dictionary_ID |
775333 |
|
| PDQ_Closed_Trial_Search_ID |
775333 |
|
| PDQ_Open_Trial_Search_ID |
775333 |
|
| Preferred_Name |
Nateglinide |
|
| prefixIRI |
NCIT:C61858 |
|
| prefLabel |
Nateglinide |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0903898 |
|
| subClassOf |